Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Drug |
Pharmacologic Class |
Indication |
More Information |
| Endocrine Disorders | |||
| Brenzavvy (bexagliflozin) | Sodium-glucose cotransporter 2 inhibitor | As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. | Brenzavvy Approved for Adults With Type 2 Diabetes |
| Neurologic Disorders | |||
| Leqembi (lecanemab-irmb) | Amyloid beta-directed antibody. | Treatment of Alzheimer disease. | Leqembi Drug Monograph |
| Oncology | |||
| Brukinsa (zanubrutinib) | Small molecule inhibitor of Bruton tyrosine kinase | For the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. | Brukinsa Drug Monograph |
| Jaypirca (pirtobrutinib) | Noncovalent inhibitor of BTK | Treatment of adult patients with relapsed or refractory mantle cell lymphoma after at least 2 lines of systemic therapy, including a BTK inhibitor. | Jaypirca Approved for Relapsed/Refractory Mantle Cell Lymphoma |
| Keytruda (pembrolizumab) | Programmed death receptor-1 blocking antibody | For adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB, II, or IIIA non-small cell lung cancer. | Keytruda Approved as Adjuvant Treatment for Stage IB, II, or IIIA NSCLC |
| Orserdu (elacestrant) | Estrogen receptor antagonist | Treatment of postmenopausal women or adult men with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy. | Orserdu Approved for ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer |
| Tukysa (tucatinib) | Tyrosine kinase inhibitor | In combination with trastuzumab for the treatment of adults with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. | Tukysa Drug Monograph |
| Psychiatric Disorders | |||
| Rykindo (risperidone) | Atypical antipsychotic | Treatment of schizophrenia in adults, and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults. | Rykindo Approved for Schizophrenia, Bipolar Disorder |
Please login or register first to view this content.
